CNS Pharmaceuticals holds annual shareholder meeting, elects directors

• CNS Pharmaceuticals held its annual shareholder meeting on Sept. 30, 2026.
• Shareholders endorsed amendments to the 2020 Equity Plan, lifting authorized share issuance under the plan by 650,000 to 765,061.
• Investors also backed the selection of MaloneBailey, LLP as independent registered public accounting firm for the year ending Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-007552), on October 02, 2026, and is solely responsible for the information contained therein.